BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Cynata Introduces a Scalable Mesenchymal Stem Cell (MSC) Manufacturing Platform
Power of a Scalable MSC Manufacturing Technology

Cynata Introduces a Scalable Mesenchymal Stem Cell (MSC) Manufacturing Platform

October 19, 2015 By Cade Hildreth (CEO) Leave a Comment

Cynata TherapeuticsCynata Therapeutics is a regenerative medicine company,  listed on the Australian exchange with the ticker symbol CYP (ASX: CYP). The company recently broke onto the regenerative medicine scene by developing Cymerus™, a therapeutic stem cell platform technology that utilizes discoveries made at the University of Wisconsin-Madison (UWM).

Discover class-defining bioproduction tools.

UWM is a world-renowned leader in stem cell research that is best known for the work by Professor James Thomson’s research team, which succeeded in first isolating human embryonic stem cells (hESCs) in 1998 and successfully producing induced pluripotent stem cells (iPSCs) from human adult cells in 2007.

Cynata co-founder, Professor Igor Slukvin, was a member of the team that conducted UWM’s pioneering iPSC research. UWM is also infamous for its strong patent positions pertaining to the process of human embryonic stem cell (hESC) derivation. 

Economic Manufacture of MSCs on a Commercial Scale is Limiting Factor to Therapeutic Use

In a world first, Cynata is using its proprietary Cymerus™ technology to address the main bottleneck limiting therapeutic use of mesenchymal stem cells (MSCs), which is that existing methods for the production of MSCs do not achieve economic manufacture of the cells at commercial scale. This opens up a wide range of therapeutic and manufacturing possibilities for Cynata Therapeutics.

Rooster DevServices

In the video below, Cynata Managing Director and CEO, Dr. Ross MacDonald discusses the  Cymerus™ technology, including how it will make the process of mesechymal stem cell (MSC) manufacturing scalable, reproducible, and economical.  Interestingly, the process only requires a single donor to provide the source tissue for the MSC manufacturing,  a pretty incredible feat. Dr. MacDonald also discusses the commercial benefits of the technology and how the manufacturing platform will position the company for future success within the marketplace.

bitbio

To learn more about Cynata Therapeutics, view BioInformant’s exclusive interview with Dr. Ross Macdonald.

Rate this post

Filed Under: MSCs, Stem Cells Tagged With: cell therapy, cynata therapeutics, manufacturing, mesenchymal stem cells, regenerative medicine, stem cell stocks

Related

About Cade Hildreth (CEO)

Cade Hildreth is the Founder of BioInformant.com, the world's largest publisher of stem cell industry news. Cade is a media expert on stem cells, recently interviewed by the Wall Street Journal, Los Angeles Business Journal, Xconomy, and Vogue Magazine. 

Tell Us What You Think! Cancel reply

Nanocellect

Marathon Products

Kimera Society

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram

Cart

Featured Posts

clean meat market

Clean Meat Market: Stem Cell Derived “Clean Meat” Attracts Billionaires

what are exosomes | definition

What are Exosomes, Exactly?

Who discovered stem cells?

Who Discovered Stem Cells? The Answers Revealed

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.